Celina G. Kleer
Department of Pathology,
University of Michigan School of Medicine,
Dr. Kleer received her medical degree from the University of Buenos Aires School of Medicine in Buenos Aires, Argentina in 1993. She began her residency in Anatomic and Clinical Pathology at the Mayo Clinic in Rochester, Minnesota, and completed her training at the University of Michigan in 1999. During her last year of training, she served as a Surgical Pathology Fellow with special interest in breast pathology under the mentorship of Dr. Harold Oberman. In 1999 she joined the faculty as an Assistant Professor, was promoted to Associate Professor with tenure in 2005, and to full Professor with tenure in 2011. In 2007, Dr. Kleer was honored as the first Harold A. Oberman Collegiate Professor in Pathology, a position she currently holds. In addition, she is the chief of the Breast Pathology Program at the University of Michigan. She has been an active member of the Breast Care Center since 1999. Dr. Kleer is the principal investigator of an NIH and DOD-funded research laboratory at the Cancer Center working to understand mechanisms of breast cancer invasion and metastasis, and to develop useful breast tissue-based biomarkers. Her work bridges basic science and clinical application. Dr. Kleer has been participating in NIH and DOD study sections, and was a permanent member of the NIH Study Section Tumor Progression and Metastasis from 2008-2012. In addition to her research and clinical work, Dr. Kleer is a dedicated mentor to medical students, graduate students, and physicians both in the laboratory and in surgical pathology. Many of Dr. Kleer?s trainees have gone on to highly successful academic careers in the US and abroad. In 2013, she was the distinguished recipient of the Ramzi Cotran Young Investigator Award from the United States and Canadian Academy of Pathology. In 2014, Dr. Kleer was inducted into the League of Research Excellence at the University of Michigan Medical School and into the American Society for Clinical Investigation (ASCI).
The Kleer laboratory studies the mechanism by which overepression of EZH2 and down-regulation of CCN6 (WISP3) promote breast cancer invasion and metastasis, and their utility as novel tissue biomarkers of prognosis